Probiotics in PBC Patients of Poor Response to UDCA

Sun Yat-sen University60 enrolled

Overview

The safety and efficacy of probiotics in primary biliary cholangitis (PBC) patients with poor ursodeoxycholic acid (UDCA) response.

PBC patients with poor ursodeoxycholic acid (UDCA) response are selected and randomly assigned into probiotic group and control group. Patients in probiotic group receive probiotic(Micro V Probiotics) combined UDCA for 6 months and then continue to take UDCA alone. Patients in control group continue to take UDCA alone. Biochemical indicators, immunological indicators, liver stiffness, and ultrasound of the two groups of patients were collected. GLOBE and UK-PBC scoring system are used to assesse prognosis.The feces and serum of all patients are collected to observe the differences in fecal microbial polymorphisms in the two groups of patients. Metabolomics are used to study the differences in the bile acids and short chain fatty acid metabolites of the serum and feces of the two groups of PBC patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Primary Biliary Cholangitis (PBC)

Interventions

ProbioticDRUG

UDCA combined probiotic

PlaceboDIETARY_SUPPLEMENT

UDCA combined placebo

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. PBC patients (diagnosed with PBC according to 2009 AASLD PBC PRACTICE GUIDANCE), take UDCA more than 12 months and have poor response; 2. Age 18-70 years. Exclusion Criteria: 1. Any other liver disesases (viral hepatitis, HIV positive, alcohol abuse, hemochromatosis, hepatolenticular degeneration, α1-antitrypsin deficiency and so on); 2. Important organ dysfunction such as heart, lung and kidney which affect the life expectancy; 3. Have congenital galactosemia, glucose malabsorption syndrome or lactase deficiency. 4. Patients allergic to research drugs or excipients; 5. Pregnant or lactating women; 6. Not signed informed consent; 7. Have antibiotics one month before enrollment; 8. Microecological preparations (probiotics, prebiotics, synbiotics, etc.) were used before the enrollment; 9. Malignant tumors, nerves and mental disorders; 10. Those who participated in other drug clinical trials in the past 3 months.

Locations (1)

Third Affliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

Outcomes

Primary Outcomes

Biochemical response

Percentage of patients with biochemical response (serum ALP(U/L) or GGT(U/L) decreased by 20% from baseline)

Time frame: 6 month

Central Contacts

Bingliang Lin, MD

CONTACT

13924129928 lamikin@126.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.